Tadalafil oral film - IntelGenx

Drug Profile

Tadalafil oral film - IntelGenx

Alternative Names: INT-007; INT0007; INT0007/2006; Tadalafil - IntelGenx; Tadalafil film - IntelGenx

Latest Information Update: 28 Nov 2016

Price : $50

At a glance

  • Originator IntelGenx Corp.
  • Class Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Erectile dysfunction

Most Recent Events

  • 21 Nov 2016 IntelGenx signed binding term sheet for license to tadalafil dosing patent of Eli Lilly
  • 21 Nov 2016 IntelGenx announces intention to submit NDA to the US FDA in second quarter of 2017
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top